Abstract
Summary
Men treated by androgen deprivation therapy (ADT) for localized prostate cancer are at risk for fracture, but it is not known which men require pharmacologic treatment. We found that 33% of men on ADT had osteoporosis of spine, hip, or forearm by dual-energy X-ray absorptiometry (DXA), thus requiring treatment. Using the new fracture prediction algorithm (FRAX™) tool with corrected femoral neck T-score identified only 17% requiring treatment, and, if calculated without femoral neck, 54% were identified to need treatment.
Introduction
Men treated with androgen deprivation therapy (ADT) for prostate carcinoma live long enough to fracture. A new fracture prediction method, FRAX™, is based on femoral neck DXA plus risk factors. Thus, DXA or FRAX™ could determine which men should receive osteoporosis therapy.
Methods
Of 115 men undergoing ADT referred for DXA testing, those with bone mineral density (BMD) in spine, hip, or forearm of ≥2.5 standard deviations below a normal male ethnicity-adjusted mean were considered treatment candidates. Using FRAX™ with and without femoral neck BMD, men were treatment candidates if the 10-year hip fracture risk was ≥3% or the major osteoporotic fracture risk was ≥20%.
Results
The men averaged 77 years old; 58% were African–American, and 14.8% were current smokers. Mean femoral neck T-score was −1.4. Using DXA, 38 (33%) men would need treatment. When FRAX™ was calculated including the femoral neck T-score, only 20 men met criteria for treatment. However, when FRAX™ was calculated without the T-score, 62 men met criteria for treatment. Overlap among the groups was surprisingly modest.
Conclusions
DXA and FRAX™ identify different ADT men for treatment.
Similar content being viewed by others
References
Adler RA (2006) The need for increasing awareness of osteoporosis in men. Clin Cornerstone 8(Suppl 3):S7–S13
Daniell HW (1997) Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439–444
Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656–3661
Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410–6417
Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J (2006) Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175:136–139
Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA (2005) Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 16:707–711
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164
Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL (2008) Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300:173–181
Qaseem A, Snow V, Shekelle P, Hopkins RH Jr, Forciea MA, Owens DK (2008) Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 148:680–684
Hochberg MC, Adler RA (2008) Screening for osteoporosis in men: comment on the American College of Physician’s clinical guidelines. Nat Clin Pract Rheumatol 4:626–627
Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, Orwoll ES (2006) Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 91:3908–3915
Siris E, Delmas PD (2008) Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporos Int 19:383–384
Dawson-Hughes B, Tosteson ANA, Melton LJ III, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449–458
De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:133901338
ISCD (2007) ISCD official positions 2007. www.iscd.org. Accessed August 2008
Tosteson ANA, Melton LJ III, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the U.S. perspective from the National Osteoporosis Foundation Guide Committee. Osteoporos Int 19:437–447
Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610
Ringe JD, Faber H, Farahmand P, Dorst A (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:296–300
Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17
Tracy JK, Meyer WA, Grigoryan M et al (2006) Racial differences in the prevalence of vertebral fractures in older men: the Baltimore Men’s Osteoporosis Study. Osteoporos Int 17:99–104
Sridhar G, Adera T, Ramakrishnan R, Roberts JD, Nelson CMK, Masho SW (2008) Racial disparities in prostate cancer survival: a meta-analysis. American Public Health Association Annual Meeting #190878 (abstract)
Greenspan SL (2008) Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 93:2–7
Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner S (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008–2012
Smith MR, Fallon MA, Lee H, Finkelstein JS (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841–3846
Greenspan SL, Nelson JB, Trump DL, Resnick NM (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. Ann Intern Med 146:416–424
Conflicts of interest
RAA: Research Support: Novartis, Procter and Gamble, Eli Lilly; Consultation: Merck, Eli Lilly; Speaking: Novartis
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Adler, R.A., Hastings, F.W. & Petkov, V.I. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX™. Osteoporos Int 21, 647–653 (2010). https://doi.org/10.1007/s00198-009-0984-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-009-0984-0